40 results on '"Guenthner, Scott"'
Search Results
2. Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study
3. Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
4. COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug–Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts
5. Efficacy of Tapinarof Cream 1% Once Daily for the Treatment of Mild to Severe Intertriginous Plaque Psoriasis
6. Tapinarof Cream 1% Once Daily Improves Patient-reported Outcomes in the Treatment of Mild to Severe Intertriginous Plaque Psoriasis
7. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
8. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis
9. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: Results from the Phase 2b CONTROL study
10. Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial
11. Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application
12. Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis
13. The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
14. The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis
15. Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application
16. 31865 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis
17. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study.
18. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry
19. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
20. A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis
21. 25995 5-year efficacy of tildrakizumab 100 and 200 mg by PASI 50/75/90/100 and PGA in reSURFACE 1
22. 43759 Insights Into Baseline Demographics and Disease Characteristics in Subjects With Notalgia Paresthetica
23. 42297 Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
24. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
25. 15908 Long-term efficacy and safety of brodalumab in patients with or without metabolic syndrome
26. 15904 Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1
27. A phase II study of photodynamic therapy (PDT) with aminolevulinic acid HCl (ALA) 20% topical solution + blue light vs ALA topical solution vehicle + blue light using spot and broad area application and incubation times of 1, 2 and 3 hours for the treatment: P6350
28. The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study
29. Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials
30. Baseline Characteristics of Atopic Dermatitis (AD) and AD Treatments in a Cohort of Adult AD Patients Initiating Dupilumab in a Real-World Registry (PROSE)
31. Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials
32. Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants
33. Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies
34. A skin cancer education initiative at a professional baseball game and results of a skin cancer survey
35. Abnormal Hair Growth in a Child With Atopy
36. Quantifying skin photodamage with spatial frequency domain imaging: statistical results
37. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: A clinicopathologic correlation
38. Inter- and Intra-physician variation in quantifying actinic keratosis skin photodamage.
39. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.
40. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.